Boehringer seeks European approval for expanded indication of tiotropium Respimat

German pharmaceutical firm Boehringer Ingelheim has submitted European marketing authorisation (MA) applications to extend the indication to use tiotropium (Spiriva) Respimat for the treatment of asthma in adults aged 18 years and over.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news